[헬스코리아뉴스]The U.S. Food and Drug Administration(FDA) accepted the IND(Investigational New Drug) application for 'GCC1290K' which Green cross has been developing as new drug for treatment of Parkinson's disease.
Parkinson's disease is a degenerative disorder of the central nervous system that often impairs the sufferer's motor skills, speech, and other functions.
According to Kim Jung-Min, managing director of Green cross, 'GCC1290K' has shown its safety and effectiveness, successfully passing the animal testing phase, and it can also treat some side effects of conventional drugs.
This is the first time that the FDA accepted the IND application for a drug under development by purely domestic technology for the treatment of patients with Parkinson's disease.
Green cross has applied for patents on the chemicals substances and purpose of the drug in 16 countries including U.S.A and Europe.